Arvinas developed an ER-targeting PROTAC, ARV-471 (Fig. 2h), which was approved by the FDA to enter clinical trial for the treatment of patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer [137]. This evidence concerns the gene ESR1 and breast carcinoma.